Study Rationale: As Parkinson’s disease (PD) progresses, one of the molecular changes that occurs is an increase in the number of phosphate groups that are added to proteins. In this project, we will develop a tool for measuring the phosphorylation levels of several proteins implicated in the pathogenesis of PD: LRRK2, RAB10, RAB12 and RAB29 (the latter representing proteins that interact with LRRK2).
Hypothesis: We hypothesize that a “multiplexed ELISA” that can measure simultaneously the phosphorylation levels of LRRK2, RAB10, RAB12 and RAB29 will provide a valuable tool for monitoring PD progression.
Study Design: Our team at Quansys Biosciences will take advantage of the company’s decade of experience with multiplexed ELISAs to develop a tool for monitoring phosphorylation of these four PD-associated proteins. We will begin by carrying out feasibility studies and testing. Next, we will characterize and optimize the assay. We will then verify the assay and transfer it to production. In the final phase, we will validate and commercialize the assay.
Impact on Diagnosis/Treatment of Parkinson’s disease: This new tool will allow for easier and faster detection of phosphorylation on several proteins associated with PD all in one single assay.
Next Steps for Development: If the project is successful, the next steps would be to do the required validation for further clinical use, as this assay is being developed for Research Use Only.